Similar Papers

Paper Title
Journal
Date
Author
Abstract 1555: Monoclonal antibodies targeting the TAM family of receptor tyrosine kinases
Diego Alvarado ...
Cancer Research | VOL. 79
Diego Alvarado, et. al.Diego Alvarado ...
01 Jul 2019
Axl Receptor Axis: A New Therapeutic Target in Lung Cancer
Pavel A Levin ... David E Gerber
Journal of Thoracic Oncology | VOL. 11
Pavel A Levin, et. al.Pavel A Levin ... David E Gerber
26 Apr 2016
Abstract 3968: AXL is responsible for much of TKI-mediated adaptive resistance in FLT3/ITD AML cells
Tessa Seale ... Bao Nguyen
Cancer Research | VOL. 82
Tessa Seale, et. al.Tessa Seale ... Bao Nguyen
15 Jun 2022
Abstract 2627: Inhibition of TGFβ in colorectal cancer cells is associated with a compensatory activation of AXL and p38 MAPK signaling pathways
Davide Ciardiello ... Giusi Barra
Cancer Research | VOL. 79
Davide Ciardiello, et. al.Davide Ciardiello ... Giusi Barra
01 Jul 2019
View more papers

More From: Journal for ImmunoTherapy of Cancer

Paper Title
Journal
Date
Author
Real-world outcomes with tisagenlecleucel in aggressive B-cell lymphoma: subgroup analyses from the CIBMTR registry
Daniel J Landsburg ... Cameron J Turtle
Journal for ImmunoTherapy of Cancer | VOL. 13
Daniel J Landsburg, et. al.Daniel J Landsburg ... Cameron J Turtle
09 Feb 2025
Phase I study of efineptakin alfa (NT-I7) for the treatment of Kaposi sarcoma
Ramya Ramaswami ... Chia-Ching Jackie Wang
Journal for ImmunoTherapy of Cancer | VOL. 13
Ramya Ramaswami, et. al.Ramya Ramaswami ... Chia-Ching Jackie Wang
06 Feb 2025
Complete metabolic response as early predictor of long-term efficacy after adoptive T cell therapy using tumor-infiltrating lymphocytes
Troels Holz Borch ... Inge Marie Svane
Journal for ImmunoTherapy of Cancer | VOL. 13
Troels Holz Borch, et. al.Troels Holz Borch ... Inge Marie Svane
06 Feb 2025
Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study
Michiel M Smeenk ... Willemijn S M E Theelen
Journal for ImmunoTherapy of Cancer | VOL. 13
Michiel M Smeenk, et. al.Michiel M Smeenk ... Willemijn S M E Theelen
06 Feb 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.